Prestige BioPharma Limited

Prestige BioPharma Limited is a biopharmaceutical company based in Singapore that researches, develops, and markets biosimilars, antibody drugs, and vaccines. Its portfolio includes a Trastuzumab biosimilar for breast cancer, a Bevacizumab biosimilar for oncology, and PBP1502, an adalimumab biosimilar in Phase 1 trials for immunology. The company also develops PBP1510, a first-in-class antibody in Phase 1/2a trials for pancreatic cancer, and several other antibodies and biosimilars across immunology, endocrinology, oncology, haematology, and dermatology. Incorporated in 2015, it is headquartered in Singapore.